RERE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. Despite strong Q3 growth, the stock is weakening short-term (down -3.88% today, MACD histogram negative and expanding) and there are no Intellectia buy signals to justify jumping in immediately. With price sitting near the 5.92 pivot and the pattern-based outlook skewing negative over the next month (-8.8%), the risk/reward for buying right now is unattractive.
Trend/structure: Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting a broader uptrend remains intact. Momentum: MACD histogram is -0.0195 and negatively expanding, signaling weakening momentum and increasing downside pressure in the near term. RSI_6 is 52.37 (neutral), so there is no oversold bounce signal to lean on. Key levels: Pivot 5.92 is the immediate line in the sand. Below it, support sits at S1 5.655 then S2 5.49. Overhead resistance is R1 6.185 then R2 6.35. Current price (5.965) is only slightly above the pivot, so a small drop can put the stock into a more fragile technical zone. Pattern-based expectation: Similar-pattern stats imply modest upside odds over 1 day (+1.31%) and 1 week (+3.93%), but a negative bias over 1 month (-8.8%), which conflicts with an impatient buy-now approach.
Intellectia Proprietary Trading Signals
with material YoY acceleration: revenue +27.10% YoY, net income +407.84% YoY, EPS +409.09% YoY. Gross margin improved to 12 (+5.45% YoY), supporting profitability momentum.
Near-term momentum is deteriorating (MACD histogram below zero and expanding negatively) while the stock is down -3.88% in the regular session.
No recent news in the past week, meaning no fresh catalyst to reverse the current weakness.
Similarity-pattern forecast is negative over the next month (-8.8%), which is unfavorable for a buy-now, impatient posture.
Hedge funds and insiders show neutral activity (no supportive accumulation trend indicated).
Latest quarter: 2025/Q3. Revenue increased to 5,149,155,000 (+27.10% YoY). Net income rose to 90,817,000 (+407.84% YoY). EPS increased to 0.56 (+409.09% YoY). Gross margin improved to 12 (+5.45% YoY). Overall, fundamentals show strong growth and improving profitability in the latest quarter.
No analyst rating or price target change data was provided, so recent Wall Street rating/target trend cannot be verified from the dataset. Pros view (based on provided data): strong Q3 growth in revenue, earnings, and improving margin suggests improving business quality. Cons view (based on provided data): current tape is weak (negative/expanding MACD, sharp down day) and there is no near-term catalyst or strong institutional/insider trend indicated; for an impatient entry, the setup is not compelling. Politicians/congress: No recent congress trading data available (last 90 days).
